Compensatory mechanisms in genetic models of neurodegeneration: Are the mice better than humans?

Frontiers in Cellular Neuroscience

Volumn 9, Issue , 2015, Pages

  Kreiner, Grzegorz ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Alzheimer s disease; Compensation; Genetic models; Huntington s disease; Neurodegeneration; Parkinson s disease; Transgenic mice

Indexed keywords

METALLOPROTEINASE; NEUROTROPHIN; NORADRENALIN; PROTEIN KINASE C DELTA; TAU PROTEIN;

ALZHEIMER DISEASE; AUTOPHAGY; GENE CONTROL; GENE MUTATION; GENE OVEREXPRESSION; GENE REPLICATION; GENETIC ENGINEERING; GENETIC MODEL; GLYCOLYSIS; HUMAN; HUNTINGTON CHOREA; MENTAL DEFICIENCY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHYSICAL DISABILITY; PROTEIN PHOSPHORYLATION; REVIEW; TRANSGENIC ANIMAL;

EID: 84939637813     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2015.00056     Document Type: Review

References (49)

1. Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., and Davies, P. (2005). Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci. 25, 5446-5454. doi: 10.1523/jneurosci.4637-04.2005
2. Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K. L., Barde, Y. A., et al. (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590. doi: 10.1046/j.1471-4159.2003.01879.x
3. Bakhoum, M. F., Bakhoum, C. Y., Ding, Z., Carlton, S. M., Campbell, G. A., and Jackson, G. R. (2014). Evidence for autophagic gridlock in aging and neurodegeneration. Transl. Res. 164, 1-12. doi: 10.1016/j.trsl.2014.01.016
4. Beal, M. F. (2010). Parkinson's disease: a model dilemma. Nature 466, S8-S10. doi: 10.1038/466s8a
5. Besusso, D., Geibel, M., Kramer, D., Schneider, T., Pendolino, V., Picconi, B., et al. (2013). BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior. Nat. Commun. 4:2031. doi: 10.1038/ncomms3031
6. Bezard, E., Yue, Z., Kirik, D., and Spillantini, M. G. (2013). Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov. Disord. 28, 61-70. doi: 10.1002/mds.25108
7. Carrasco, D. I., Bichler, E. K., Rich, M. M., Wang, X., Seburn, K. L., and Pinter, M. J. (2012). Motor terminal degeneration unaffected by activity changes in SOD1(G93A) mice; a possible role for glycolysis. Neurobiol. Dis. 48, 132-140. doi: 10.1016/j.nbd.2012.06.017
8. Chang, C., and Werb, Z. (2001). The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11, S37-S43. doi: 10.1016/s0962-8924(01)82222-4
9. Chen, R. H., Sarnecki, C., and Blenis, J. (1992). Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol. Cell. Biol. 12, 915-927.
10. Chesselet, M. F., and Richter, F. (2011). Modelling of Parkinson's disease in mice. Lancet Neurol. 10, 1108-1118. doi: 10.1016/s1474-4422(11)70227-7
11. Counts, S. E., and Mufson, E. J. (2010). Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J. Neurochem. 113, 649-660. doi: 10.1111/j.1471-4159.2010.06622.x
12. de Oca Balderas, P. M., Ospina, G. G., and Del Ángel, A. S. (2013). Mitochondrial impairment induced by 3-nitropropionic acid is enhanced by endogenous metalloprotease activity inhibition in cultured rat striatal neurons. Neurosci. Lett. 546, 16-20. doi: 10.1016/j.neulet.2013.04.041
13. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Perez-Tur, J., et al. (1996). Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713. doi: 10.1038/383710a0
14. Elder, G. A., Gama Sosa, M. A., and De Gasperi, R. (2010). Transgenic mouse models of Alzheimer's disease. Mt. Sinai J. Med. 77, 69-81. doi: 10.1002/msj.20159
15. Eriksen, J. L., and Janus, C. G. (2007). Plaques, tangles and memory loss in mouse models of neurodegeneration. Behav. Genet. 37, 79-100. doi: 10.1007/s10519-006-9118-z
16. Faria, M. C., Gonçalves, G. S., Rocha, N. P., Moraes, E. N., Bicalho, M. A., Gualberto Cintra, M. T., et al. (2014). Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease. J. Psychiatr. Res. 53, 166-172. doi: 10.1016/j.jpsychires.2014.01.019
17. Giordano, S., Darley-Usmar, V., and Zhang, J. (2013). Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol. 2, 82-90. doi: 10.1016/j.redox.2013.12.013
18. Glick, D., Barth, S., and Macleod, K. F. (2010). Autophagy: cellular and molecular mechanisms. J. Pathol. 221, 3-12. doi: 10.1002/path.2697
19. Gotz, J., Probst, A., Spillantini, M. G., Schäfer, T., Jakes, R., Bürki, K., et al. (1995). Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 14, 1304-1313.
20. Griner, E. M., and Kazanietz, M. G. (2007). Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 7, 281-294. doi: 10.1038/nrc2110
21. Kadoguchi, N., Okabe, S., Yamamura, Y., Shono, M., Fukano, T., Tanabe, A., et al. (2014). Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease. BMC Neurosci. 15:79. doi: 10.1186/1471-2202-15-79
22. Kazim, S. F., Blanchard, J., Dai, C. L., Tung, Y. C., LaFerla, F. M., Iqbal, I. G., et al. (2014). Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 71, 110-130. doi: 10.1016/j.nbd.2014.07.001
23. Kreiner, G., Bierhoff, H., Armentano, M., Rodriguez-Parkitna, J., Sowodniok, K., Naranjo, J. R., et al. (2013). A neuroprotective phase precedes striatal degeneration upon nucleolar stress. Cell Death Differ. 20, 1455-1464. doi: 10.1038/cdd.2013.66
24. Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Wittorf, A., Richartz, E., et al. (2006). Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural Transm. 113, 1217-1224. doi: 10.1007/s00702-005-0397-y
25. Li, J. Y., Popovic, N., and Brundin, P. (2005). The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2, 447-464. doi: 10.1602/neurorx.2.3.447
26. Lin, C. H., Tallaksen-Greene, S., Chien, W. M., Cearley, J. A., Jackson, W. S., Crouse, A. B., et al. (2001). Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10, 137-144. doi: 10.1093/hmg/10.2.137
27. MacDonald, M. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group. Cell 72, 971-983. doi: 10.1016/0092-8674(93)90585-e
28. Masliah, E., Sisk, A., Mallory, M., and Games, D. (2001). Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. J. Neuropathol. Exp. Neurol. 60, 357-368.
29. Nelson, A. R., Kolasa, K., and McMahon, L. L. (2014). Noradrenergic sympathetic sprouting and cholinergic reinnervation maintains non-amyloidogenic processing of AβPP. J. Alzheimers Dis. 38, 867-879. doi: 10.3233/JAD-130608
30. Oyama, F., Sawamura, N., Kobayashi, K., Morishima-Kawashima, M., Kuramochi, T., Ito, M., et al. (1998). Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid β-protein 42 in the brain. J. Neurochem. 71, 313-322. doi: 10.1046/j.1471-4159.1998.71010313.x
31. Parlato, R., and Kreiner, G. (2013). Nucleolar activity in neurodegenerative diseases: a missing piece of the puzzle?J. Mol. Med. (Berl.) 91, 541-547. doi: 10.1007/s00109-012-0981-1
32. Pickrell, A. M., Pinto, M., Hida, A., and Moraes, C. T. (2011). Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 31, 17649-17658. doi: 10.1523/JNEUROSCI.4871-11.2011
33. Pickrell, A. M., Pinto, M., and Moraes, C. T. (2013). Mouse models of Parkinson's disease associated with mitochondrial dysfunction. Mol. Cell. Neurosci. 55, 87-94. doi: 10.1016/j.mcn.2012.08.002
34. Pierce, A. A., and Xu, A. W. (2010). De novo neurogenesis in adult hypothalamus as a compensatory mechanism to regulate energy balance. J. Neurosci. 30, 723-730. doi: 10.1523/JNEUROSCI.2479-09.2010
35. Przedborski, S., Jackson-Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., et al. (2001). The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265-1274. doi: 10.1046/j.1471-4159.2001.00183.x
36. Ribeiro, F. M., Camargos, E. R., de Souza, L. C., and Teixeira, A. L. (2013). Animal models of neurodegenerative diseases. Rev. Bras. Psiquiatr. 35(Suppl. 2), S82-S91. doi: 10.1590/1516-4446-2013-1157
37. Rommelfanger, K. S., and Weinshenker, D. (2007). Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 74, 177-190. doi: 10.1016/j.bcp.2007.01.036
38. Rommelfanger, K. S., Weinshenker, D., and Miller, G. W. (2004). Reduced MPTP toxicity in noradrenaline transporter knockout mice. J. Neurochem. 91, 1116-1124. doi: 10.1111/j.1471-4159.2004.02785.x
39. Rué, L., Alcalá-Vida, R., López-Soop, G., Creus-Muncunill, J., Alberch, J., and Pérez-Navarro, E. (2014). Early down-regulation of PKCδ as a pro-survival mechanism in Huntington's disease. Neuromolecular Med. 16, 25-37. doi: 10.1007/s12017-013-8248-8
40. Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., and Teixeira, A. L. (2010). Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J. Neurol. 257, 540-545. doi: 10.1007/s00415-009-5357-2
41. Scholz, S. W., Mhyre, T., Ressom, H., Shah, S., and Federoff, H. J. (2012). Genomics and bioinformatics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2:a009449. doi: 10.1016/j.pathophys.2014.10.002
42. Schwab, C., Klegeris, A., and McGeer, P. L. (2010). Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim. Biophys. Acta 1802, 889-902. doi: 10.1016/j.bbadis.2009.10.013
43. Seredenina, T., Gokce, O., and Luthi-Carter, R. (2011). Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation. PLoS One 6:e22231. doi: 10.1371/journal.pone.0022231
44. Srinivasan, J., and Schmidt, W. J. (2003). Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur. J. Neurosci. 17, 2586-2592. doi: 10.1046/j.1460-9568.2003.02684.x
45. Wiedlocha, M., Stańczykiewicz, B., Jakubik, M., and Rymaszewska, J. (2012). [Selected mice models based on APP, MAPT and presenilin gene mutations in research on the pathogenesis of Alzheimer's disease]. Postepy Hig. Med. Dosw. (Online) 66, 415-430. doi: 10.5604/17322693.1001098
46. Xifro, X., Anglada-Huguet, M., Rué, L., Saavedra, A., Pérez-Navarro, E., and Alberch, J. (2011). Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity. Mol. Neurodegener. 6:74. doi: 10.1186/1750-1326-6-74
47. Zaman, V., Nelson, M. E., Gerhardt, G. A., and Rohrer, B. (2004). Neurodegenerative alterations in the nigrostriatal system of trkB hypomorphic mice. Exp. Neurol. 190, 337-346. doi: 10.1016/j.expneurol.2004.08.002
48. Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337-341. doi: 10.1001/archneur.60.3.337
49. Zuccato, C., and Cattaneo, E. (2014). Huntington's disease. Handb. Exp. Pharmacol. 220, 357-409. doi: 10.1007/978-3-642-45106-5_14